AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11268113 — intervention group
Group type: COMPARATOR
Intervention: 1% peppermint oil
Number of subjects: 41
Study 11268113 — intervention group
Group type: COMPARATOR
Intervention: 0.5% peppermint oil
Number of subjects: 41
Study 11268113 — intervention group
Group type: COMPARATOR
Intervention: 0.1% peppermint oil
Number of subjects: 41
Study 11268113 — intervention group
Group type: COMPARATOR
Intervention: 0% peppermint oil
Number of subjects: 41
Study 9640160 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.025 microgram kg‐1 min‐1
Number of subjects: 0
Study 9640160 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microgram kg‐1 min‐1
Number of subjects: 0
Study 9640160 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rate 6 mg kg‐1 h‐1
Number of subjects: 0
Study 9640160 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.025‐0.05 microgram kg‐1 min‐1
Number of subjects: 0
Study 7856286 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril 3 x 12.5 mg, lisinopril 1 x 10 mg, enalapril 1 x 10 mg)
Number of subjects: 31
Study 7856286 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril, lisinopril, enalapril)
Number of subjects: 31
Study 7856286 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors with acetylsalicylic acid
Number of subjects: 31
Study 2530717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐Ar (1-inch needle injection in the arm)
Number of subjects: 3
Study 2530717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐Bu (1-inch needle injection in the buttock)
Number of subjects: 3
Study 2530717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐Bu (2-inch needle injection in the buttock)
Number of subjects: 3
Study 588914 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tomography (CT)
Number of subjects: 50
Study 588914 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 50
Study 30211826 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 83
Study 30211826 — intervention group
Group type: COMPARATOR
Intervention: CNI-based treatment
Number of subjects: 83
Study 28732433 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt therapy (staying in the salt room for one hour, three times a week for 3 consecutive weeks)
Number of subjects: 34
Study 28732433 — intervention group
Group type: COMPARATOR
Intervention: Control group (three weeks under observation)
Number of subjects: 34
Study 25803604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi plus behavioral weight loss program (TCWL)
Number of subjects: 29
Study 25803604 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 29
Study 23535113 — intervention group
Group type: EXPERIMENTAL
Intervention: External ventricular drainage (EVD) from ipsilateral ventricle (IG)
Number of subjects: 45
Study 23535113 — intervention group
Group type: COMPARATOR
Intervention: External ventricular drainage (EVD) from contralateral ventricle (CG)
Number of subjects: 45
Study 21482569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 0
Study 21482569 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 0
Study 19931751 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated weight estimates using midarm circumference and knee height measurements
Number of subjects: 0
Study 19931751 — intervention group
Group type: COMPARATOR
Intervention: Physician estimates
Number of subjects: 0
Study 19931751 — intervention group
Group type: COMPARATOR
Intervention: Nurse estimates
Number of subjects: 0
Study 19931751 — intervention group
Group type: COMPARATOR
Intervention: Patient self-reported estimates
Number of subjects: 0
Study 17467230 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (weekly for 4 months, followed by monthly sessions for 8 months)
Number of subjects: 227
Study 17467230 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 227
Study 15733403 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (8‐70 mA, 20 min, qd, for 20‐30 times)
Number of subjects: 60
Study 15733403 — intervention group
Group type: COMPARATOR
Intervention: Oral tolterodine 2 mg, bid, for 2‐4 weeks
Number of subjects: 60
Study 11738122 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive and lipid-lowering therapy
Number of subjects: 42419
Study 9624745 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling service
Number of subjects: 385
Study 8147352 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimycobacterial drugs (ethambutol, clofazimine, dapsone, and 1-day dose of rifampicin)
Number of subjects: 40
Study 8147352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3347325 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 101
Study 3347325 — intervention group
Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide (HCT)
Number of subjects: 101
Study 3347325 — intervention group
Group type: COMPARATOR
Intervention: HCT dosage doubled after 1 month
Number of subjects: 101
Study 31133624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensive intervention group
Number of subjects: 300
Study 31133624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensive intervention group
Number of subjects: 300
Study 31133624 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 27768509 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up care (valued by participants)
Number of subjects: 32
Study 27768509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly payment willingness to pay (WTP)
Number of subjects: 32
Study 27768509 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time payment willingness to pay (WTP)
Number of subjects: 32
Study 27768509 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predicting higher WTP
Number of subjects: 32
Study 27768509 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual cancer-related visits
Number of subjects: 32
Study 27768509 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement to pay for follow-up care
Number of subjects: 32
Study 25812483 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (weekly or bi-weekly assessments via texts)
Number of subjects: 0
Study 25812483 — intervention group
Group type: COMPARATOR
Intervention: Standard care (routine and urgent follow-up visits and telephone calls)
Number of subjects: 0
Study 23672202 — intervention group
Group type: EXPERIMENTAL
Intervention: Irsogladine 4 mg daily for 14 days with diclofenac sodium 75 mg
Number of subjects: 32
Study 23672202 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 10 mg daily for 14 days with diclofenac sodium 75 mg
Number of subjects: 32
Study 21799130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity PRT (3.5 times higher velocity against reduced loads)
Number of subjects: 63
Study 21799130 — intervention group
Group type: COMPARATOR
Intervention: Low-velocity PRT (shortening contractions at low velocities against high loads)
Number of subjects: 63
Study 18957313 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OCD
Number of subjects: 28
Study 17420341 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day discharge
Number of subjects: 800
Study 17420341 — intervention group
Group type: COMPARATOR
Intervention: Overnight stay
Number of subjects: 800
Study 17420341 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day discharge (suitable for early discharge)
Number of subjects: 800
Study 17420341 — intervention group
Group type: COMPARATOR
Intervention: Overnight stay (suitable for early discharge)
Number of subjects: 800
Study 15564693 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated percutaneous coronary intervention (PCI)
Number of subjects: 168
Study 11429342 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.04 microg.kg(‐1).h(‐1) (Group RC1)
Number of subjects: 55
Study 11429342 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.08 microg.kg(‐1).h(‐1) (Group RC2)
Number of subjects: 55
Study 11429342 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.12 microg.kg(‐1).h(‐1) (Group RC3)
Number of subjects: 55
Study 11429342 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.1% 0.2 mg.kg(‐1).h(‐1) (Group R)
Number of subjects: 55
Study 9589248 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin gel 100 micrograms/g
Number of subjects: 382
Study 9589248 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 382
Study 7750174 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal point acupuncture (TG)
Number of subjects: 108
Study 7750174 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture (BG)
Number of subjects: 108
Study 2532741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 99‐126 atrial natriuretic factor (ANF) infusion
Number of subjects: 0
Study 2532741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 5451146 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin‐chloramphenicol
Number of subjects: 0
Study 5451146 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin‐kanamycin
Number of subjects: 0
Study 30945431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin (TOFO)
Number of subjects: 775
Study 29574980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (an angiotensin-converting enzyme inhibitor)
Number of subjects: 120
Study 29574980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26657621 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community health promotion platform
Number of subjects: 54
Study 26657621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 22628143 — intervention group
Group type: EXPERIMENTAL
Intervention: Video games (three commercially available games)
Number of subjects: 42
Study 22628143 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Performance Test II (CPT II)
Number of subjects: 42
Study 23113480 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ivermectin lotion
Number of subjects: 765
Study 23113480 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 765
Study 20434097 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 15 mg of hyperbaric ropivacaine plus 25 microg of fentanyl
Number of subjects: 60
Study 20434097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spinal anesthesia with 10 mg of hyperbaric ropivacaine plus 25 microg of fentanyl
Number of subjects: 60
Study 20434097 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 112.5 mg of ropivacaine plus 25 microg of fentanyl
Number of subjects: 60
Study 20434097 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 16680447 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent low back pain cases (female workers with LBP)
Number of subjects: 106
Study 16680447 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (female workers without LBP)
Number of subjects: 106
Study 16680447 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT on the forehead
Number of subjects: 106
Study 16680447 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT on the lower back
Number of subjects: 106
Study 16259851 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic intervention (BDI)
Number of subjects: 70
Study 11867660 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 439
Study 11867660 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 439
Study 11867660 — intervention group
Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 439
Study 10188723 — intervention group
Group type: EXPERIMENTAL
Intervention: Degenerate PCR approach for HPV-DNA detection
Number of subjects: 117
Study 7489665 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 23
Study 7489665 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPHA)
Number of subjects: 23
Study 7489665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2318518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg once or twice daily or 50 mg once or twice daily)
Number of subjects: 0
Study 2318518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2318518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine, methyldopa, metoprolol, or reserpine (added to diuretic therapy for nonresponders)
Number of subjects: 0
Study 6931717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular and lingual osteotomy
Number of subjects: 50
Study 29474306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab combined with oral DHA supplementation (1,050 mg/day)
Number of subjects: 55
Study 29474306 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab alone (control group)
Number of subjects: 55
Study 28285845 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg once daily for 14-18 weeks
Number of subjects: 130
Study 28285845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 26096474 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster massage (60 minutes 1x/wk)
Number of subjects: 179
Study 26096474 — intervention group
Group type: COMPARATOR
Intervention: No additional massage
Number of subjects: 179
Study 26096474 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute massage groups
Number of subjects: 179
Study 22859317 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) protocol: systemic NAC infusion (30 mg/kg) 1 hour before liver procurement and locoregional NAC infusion (300 mg through the portal vein) just before cross-clamping
Number of subjects: 140
Study 22859317 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard protocol without NAC)
Number of subjects: 140
Study 22859317 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) protocol
Number of subjects: 140
Study 20093971 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized resistance training (PRT)
Number of subjects: 45
Study 20093971 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 45
Study 19696213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 589
Study 19696213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 17707639 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery +/‐ radiotherapy for localized unresectable disease
Number of subjects: 0
Study 17707639 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy +/‐ radiotherapy followed by delayed surgical resection
Number of subjects: 0
Study 17707639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with surgical resection for metastatic disease
Number of subjects: 0
Study 17707639 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ifosfamide and doxorubicin in chemotherapy regimes
Number of subjects: 0
Study 15236398 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100mg daily for 5 days)
Number of subjects: 40
Study 15236398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11878738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methylprednisolone (MP) 1 mg kg(‐1) followed by continuous infusion of MP 1.5 mg kg(‐1) for 48 hours
Number of subjects: 24
Study 11878738 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline as a bolus injection and continuous epidural infusion (P group)
Number of subjects: 24
Study 11878738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methylprednisolone (MP)
Number of subjects: 24
Study 9781732 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen
Number of subjects: 18
Study 9781732 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen
Number of subjects: 18
Study 7819468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) administered to reduce mean arterial pressure to 50 mmHg
Number of subjects: 30
Study 7819468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SNP)
Number of subjects: 30
Study 3306374 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (30 mg/kg)
Number of subjects: 382
Study 3306374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 3306374 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 382
Study 28922734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine
Number of subjects: 24
Study 28922734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2mg/kg ketamine
Number of subjects: 24
Study 28922734 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 24
Study 26872958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavioral Treatment (ABBT)
Number of subjects: 21
Study 26872958 — intervention group
Group type: COMPARATOR
Intervention: Traditional Cognitive-Behavioral Treatment (tCBT)
Number of subjects: 21
Study 24305788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative autologous blood donation (PABD) - 1 dose 72 hours prior to TKA
Number of subjects: 0
Study 24305788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative autologous blood donation (PABD) - 14 days prior to TKA
Number of subjects: 0
Study 24305788 — intervention group
Group type: COMPARATOR
Intervention: No autologous blood donation
Number of subjects: 0
Study 23774876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted elvitegravir (EVG/r; 50/100 mg QD) administered alone or with antacid simultaneously
Number of subjects: 0
Study 23774876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat-boosted elvitegravir (EVG/co; 150/150 mg QD) administered simultaneously or staggered (+12 hours) with famotidine or omeprazole
Number of subjects: 0
Study 23774876 — intervention group
Group type: EXPERIMENTAL
Intervention: Staggered antacid administration by ≥2 hours
Number of subjects: 0
Study 15752122 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA-gel therapy (aqueous 8-methoxypsoralen (8-MOP)-containing gel plus broadband UVA irradiation)
Number of subjects: 20
Study 15752122 — intervention group
Group type: COMPARATOR
Intervention: PUVA-bath therapy (8-MOP bath of the hands and/or feet plus broadband UVA)
Number of subjects: 20
Study 11812684 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA) with ropivacaine 1% (4‐mL bolus, 3‐5 mL/h infusion), fentanyl (100‐microg bolus, 15‐25 microg/h infusion), and propofol infusion (6 mg x kg(‐1) x h(‐1))
Number of subjects: 100
Study 11812684 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia with fentanyl (15 microg/kg) and propofol (5 mg x kg(‐1) x h(‐1)), followed by IV morphine patient‐controlled analgesia
Number of subjects: 100
Study 10690138 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% S(‐)‐bupivacaine
Number of subjects: 137
Study 10690138 — intervention group
Group type: COMPARATOR
Intervention: 0.25% RS‐bupivacaine
Number of subjects: 137
Study 7732155 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from partner
Number of subjects: 66
Study 7732155 — intervention group
Group type: COMPARATOR
Intervention: Social support from stranger
Number of subjects: 66
Study 7732155 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from boyfriend/girlfriend
Number of subjects: 66
Study 7732155 — intervention group
Group type: COMPARATOR
Intervention: No social support
Number of subjects: 66
Study 7732155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall subjective well-being in partner support condition
Number of subjects: 66
Study 7732155 — intervention group
Group type: COMPARATOR
Intervention: Stranger support
Number of subjects: 66
Study 1836919 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV
Number of subjects: 111
Study 1836919 — intervention group
Group type: COMPARATOR
Intervention: DT and OPV alone (control group)
Number of subjects: 111
Study 1836919 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Group III)
Number of subjects: 111
Study 1836919 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Groups I and II)
Number of subjects: 111
Study 7222859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tinofedrine (0.12 to 0.17 mg/kg body‐weight)
Number of subjects: 23
Study 30098134 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-stimulated brain glucose uptake (BGU) in obese participants
Number of subjects: 32
Study 30098134 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-stimulated brain glucose uptake (BGU) in obese participants post-bariatric surgery
Number of subjects: 32
Study 30098134 — intervention group
Group type: EXPERIMENTAL
Intervention: High insulin-stimulated BGU at baseline
Number of subjects: 32
Study 30098134 — intervention group
Group type: COMPARATOR
Intervention: Insulin-stimulated brain glucose uptake (BGU) in all participants
Number of subjects: 32
Study 30098134 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in obese participants post-bariatric surgery
Number of subjects: 32
Study 28089575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 900
Study 28089575 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 900
Study 28089575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins
Number of subjects: 900
Study 28089575 — intervention group
Group type: COMPARATOR
Intervention: Participants with fibroids
Number of subjects: 900
Study 28089575 — intervention group
Group type: COMPARATOR
Intervention: African American women with fibroids
Number of subjects: 900
Study 25762357 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD + PRF
Number of subjects: 120
Study 25762357 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD + 1% MF
Number of subjects: 120